Skip to content

The effect of low-intensity transcranial focused ultrasound stimulation of the preoptic area of the hypothalamus on sleep quality in patients with chronic insomnia: A prospective cohort study

The effect of low-intensity transcranial focused ultrasound stimulation of the preoptic area of the hypothalamus on sleep quality in patients with chronic insomnia: A prospective cohort study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125726
Enrollment
Unknown
Registered
2026-05-29
Start date
2026-05-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic insomnia

Interventions

Observation group:None

Sponsors

Zhujiang Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. It meets the diagnostic criteria for insomnia disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition(DSM-5); 2. Aged 18 to 75, right-handed; 3. Insomnia symptoms persist for more than 3 months and occur at least 3 times a week; 4. The baseline total score of the Pittsburgh Sleep Quality Index was >=8 points, the 17-item Hamilton Depression Scale was <20 points, and the 14-item Hamilton Anxiety Scale was <21points; 5. No drugs or substances acting on the nervous system have been taken in the past month, and no other neuroregulatory treatments such as transcranial electrical stimulation or transcranial magnetic stimulation have been received; 6. Be capable of receiving low-intensity transcranial ultrasound stimulation treatment and be able to cooperate to complete the collection of nuclear magnetic resonance data; 7. Sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Those with severe physical diseases, such as coronary heart disease, malignant tumors, renal failure, etc; 2. Those with concurrent organic brain diseases; 3. Those with any other mental disorders, personality disorders, or abuse or dependence on psychoactive substances; 4. Those who cannot be eluted by drug treatment; 5. Currently using drugs known to cause insomnia, such as steroids, etc; 6. Coexisting other sleep disorders, such as sleep apnea-hypopnea syndrome, rapid eye movement sleep behavior disorder, narcolepsy and restless legs syndrome, etc; 7. Those with implanted devices such as cochlear implants, pacemakers, and deep brain stimulation devices in their bodies; 8. Typical contraindications for magnetic resonance imaging (MRI) scans, such as claustrophobia; 9. Pregnant and lactating women; 10. Participate in other ongoing clinical trials at the same time.

Design outcomes

Primary

MeasureTime frame
The Pittsburgh Sleep Quality Index;

Secondary

MeasureTime frame
Heart rate (HR), heart rate variability (HRV), respiration, sleep apnea and body movement during sleep;Sleep onset latency (SOL), total sleep time (TST), and sleep efficiency (SE);The changes of electroencephalogram data before and after ultrasound stimulation;Sleep time, wake-up time, sleep time, wake-up time;Ford Stress Insomnia Response Test (FIRST) Scale, HAMA Anxiety Scale, HAMD Depression Scale, Flinders Fatigue Scale, Epworth Sleepiness Scale(ESS), Symptom Checklist 90 (SCL-90) score;Insomnia Severity Index,ISI;Functional magnetic resonance imaging(fMRI);Peripheral blood hematology, serum biochemical indicators, and single-cell transcriptomics of immune cells;

Countries

China

Contacts

Public ContactTao Tao

Zhujiang Hospital of Southern Medical University

taotao7819@126.com+86 759 3157438

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026